Genome & Company
B-8F Silicon Park, 35 Pangyo-ro 255beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea, 13486
Consent to collection and use of personal information (Required)
Genome & Company (the ”Company”) regards the protection of personal information of our users very important, and complies with relevant laws, including the Personal Information Protection Act and the Act on Expansion of Dissemination and Promotion of Utilization of Information System. The Company hereby informs the purpose and method of using the personal information provided by our users through the Company’s website, and what measures are taken to protect the personal information. If the Company revises any of this Private Policy, it will be notified through the notices on the Company’s website (or individually notified).
The Company collects the following personal information to operate its Contact Service via the Company’s website (whereby the users can make general inquires, inquiry for business development, IR inquiry, media inquiry, etc.).
- Essential Information: name, e-mail address, phone number, organization, content of inquiry
- Collection method: The Company collects the personal information through the inquiries submitted via the Contact Bulletin Board on the Company’s website.
You have the right to refuse the ‘collection of essential information’ as well as the ‘collection of optional information’. If you refuse the collection of essential information, however, you may be restricted for using the Contact Service.
The following information may be automatically generated and collected in the process of using the website.
- IP Address, cookie, date and time of visit, records of service use
The Company uses the collected personal information for the following purposes.
- Personal verification, personal identification, delivery of inquiries and notification of results (answers and responses), etc. related to the use of Contact Service
In principle, the collected personal information is destroyed without any delay after achieving the purpose of collecting and using personal information. However, the Company may keep users’ information for a certain period of time as required by relevant laws.
- Retained information: personal information submitted with the inquiry, content of the inquiry, and ensuing responses
- Relevant Law: Act on the Consumer Protection in Electronic Commerce, etc.
- Retention Period: three years (records related to resolution of consumer complaints or disputes)
In principle, the information is destroyed without any delay after achieving the purpose of collecting and using personal information. The procedure and method of destruction are as follows.
The personal information submitted is transferred to a separate database (in case of paper, separate cabinet) after achieving the purpose and kept for a certain period of time according to the internal policy and other relevant laws, before it is destroyed. The personal information transferred to separate database shall not be used any other purposes other than for keeping in accordance with laws.
2) Destruction Method
Personal information saved in the form of electronic file shall be deleted by using technical method that cannot reproduce the records. Personal information printed in the paper shall be destroyed by shredding with a shredder or incinerating it.
In case users request the correction of any errors in personal information, we shall not use or provide the personal information until such correction is made. In addition, in case incorrect personal information is already provided to a third party, we will notify the third party the result of correction without delay.
The Company processes and destroys personal information at the request of users or their legal representatives in accordance with Section ‘3. Processing of Personal Information and Retention Period’ and Section ‘4. Destruction of Personal Information’, and such information shall not be opened or used for any other purposes.
The Company designates data protection officer and manager for managing personal information as follows to protect users’ personal information related to inquiries.
Data Protection Officer
Name: Seo Yeong-jin
Department: Business management
Data Protection Manager
Name: Seol Su-gi
Department: PR team
Position: Team Lead
You can submit to the personnel above any inquiries related to your personal information submitted to the Company while using our web service. The Company will quickly provide sufficient responses to your inquiries.
Please contact the below agencies if you need report or counseling for any infringement of personal data privacy.
- Personal Information Infringement Report Center (privacy.kisa.or.kr / 118 without area code)
- Personal Information Dispute Mediation Committee (kopico.go.kr / 1833-6972)
- Cyber Investigation Department, Supreme Prosecutor’s Office (www.spo.go.kr / 1301 without area code)
- Cyber Bureau of the National Police Agency (http://cyberbureau.police.go.kr / 182 without area code)
Genome & Company is a global biopharmaceutical company that focuses on developing microbiome pharmaceuticals, consumer products and novel immune checkpoint inhibitors based on real-world clinical data and Multi-Omics analytic technology.
Since its establishment in 2015, as a global leader in the field of microbiome for immuno-oncology and novel drug discovery for immuno-oncology target, Genome & Company has been collaborating with global pharmaceutical companies, research institutions and hospitals in Korea based on the “Bed-to-Bench” approach (real-world clinical data driven R&D strategy) of GNOCLE™, a platform for discovering novel drug candidates.
Genome & Co strives to accelerate the development of innovative medicine to fulfill the medical unmet needs through microbiome therapeutics and novel drug target antibodies. We aim to grow into a fully integrated biopharmaceutical company by strengthening in-house capabilities for manufacturing and commercialization.
Applied New CI
for Genome & Company
Execution of Phase 2 Clinical Trial Collaboration
and Supply Agreement (CTCSA)
with Merck KGaA and Pfizer for GEN-001
launched research collaboration discovering novel Antibody-drug conjugate (ADC) candidates with Debiopharm
Listed on KOSDAQ
First patient dosing of GEN-001
for phase 1 in the US
Acquired majority share
of Scioto Biosciences
Execution of License Out agreement
of GEN-001 with LG Chemical
Execution of Phase 1/1b Clinical Trial Collaboration
and Supply Agreement (CTCSA)
with Merck KGaA and Pfizer for GEN-001
Series C Financing
Listed on KONEX
Series B Financing
PreA and Series A Financing
Establishment of Genome & Company Co., Ltd.
Founder & CEO
Founder & CTO
To become a fully integrated biopharmaceutical company through innovations to pharmaceutical value chains across R&D, commercialization and manufacturing